Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

American Journal of Health-System Pharmacy, Vol. 63, Issue 7, 653-656
Copyright © 2006 by American Society of Health-System Pharmacists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Washington, C.
Right arrow Articles by Berner, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Washington, C.
Right arrow Articles by Berner, B.

Reports

Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin

Carla Washington, Eddie Hou, Nicki Hughes and Bret Berner

CARLA WASHINGTON, PH.D., is Manager, Clinical Pharmacokinetics, and EDDIE HOU, PH.D., is Senior Director, Formulations and Pharmacokinetics, Depomed, Inc., Menlo Park, CA. NICKI HUGHES, PH.D., is Director, Bioanalytical Laboratory, Biovail Contract Research, Toronto, Ontario, Canada. BRET BERNER, PH.D., is Vice President, Product Development, Depomed, Inc.

Address correspondence to Dr. Berner at Depomed, Inc., 1360 O’Brien Drive, Menlo Park, CA 94025-1436 (bberner{at}depomedinc.com).


Purpose. The effect of omeprazole on the oral bioavailability and urinary exposure of the Depomed formulation of extended-release (ER) ciprofloxacin was studied.

Methods. A two-way crossover study was conducted in healthy subjects. Subjects received either a single dose of ER ciprofloxacin 1000 mg or a single dose of ER ciprofloxacin 1000 mg following three days of treatment with omeprazole 40 mg. Blood and urine samples were collected over 36 hours, and ciprofloxacin concentrations were determined using high-performance liquid chromatography.

Results. Twenty-seven subjects (16 men, 11 women) received both treatments. The mean maximum concentration, mean area under the plasma-versus-concentration curve, and mean amount of ciprofloxacin excreted in urine were similar between the two treatments and met strict bioequivalence criteria.

Conclusion. Omeprazole did not affect the plasma or urinary pharmacokinetics of an oral ER formulation of ciprofloxacin.

Index terms: Blood levels; Ciprofloxacin hydrochloride; Drug interactions; Drugs, availability; Excretion; Gastrointestinal drugs; Omeprazole; Pharmacokinetics; Quinolones; Sustained-action medications; Urine levels

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Health-System Pharmacists.